I-Mab’s Pivotal Year: Clinical Data to Steer Investor Sentiment

Biotech firm I-Mab, which will operate under the new name NovaBridge Biosciences as part of a strategic transformation, is entering a period defined by critical clinical milestones. The company’s shift to a global platform model and its advancing oncology pipeline are setting the stage for a series of data readouts that could significantly influence its market valuation.

From a liquidity perspective, I-Mab reports a solid position. Based on its last cash position update in August 2025, the company believes its existing funds are sufficient to finance operations through the fourth quarter of 2028. Investors will gain a clearer view of the financial and operational progress when the company releases its next business report on March 31, 2026. This disclosure is anticipated to provide insight into whether I-Mab can maintain its ambitious clinical trial timelines.

Givastomig: A Key Value Catalyst

The Givastomig program represents a primary driver for the company’s valuation. This bispecific antibody, targeting metastatic gastric cancer, is poised for important developments. Market participants are awaiting the publication of topline data from an ongoing Phase 1b extension study within the current quarter.

Earlier data from 2025, drawn from the dose-escalation phase, demonstrated an objective response rate (ORR) of 83%, raising expectations for the forthcoming results. Furthermore, I-Mab plans to initiate a global, randomized Phase 2 trial in the first quarter of 2026. This study will evaluate the drug candidate in combination with an immunochemotherapy as a first-line treatment.

Should investors sell immediately? Or is it worth buying I-Mab?

Strategic Shift and Pipeline Diversification

Strategically, management is implementing a "hub-and-spoke" model, where specialized subsidiaries advance individual drug candidates. This restructuring is complemented by plans for an additional stock listing in Hong Kong, aimed at creating further capital acquisition opportunities alongside its existing NASDAQ quotation.

The company is also progressing the diversification of its clinical portfolio:

• VIS-101: Developed by the subsidiary Visara, this biologic is expected to be ready for Phase 3 clinical trials during the course of 2026.
• Uliledlimab: Progression-free survival (PFS) data from a randomized Phase 2 study are anticipated in the second half of 2026.
• Ragistomig: Results from an ongoing Phase 1b study are also scheduled for release in the latter half of 2026.

The convergence of these clinical catalysts and the strategic rebranding to NovaBridge Biosciences frames a definitive period for the company, with data-driven events likely to dictate near-term equity performance.